Abbott, Rubicon in MethylPlex pact:
This article was originally published in Clinica
Executive Summary
Rubicon Genomics is to team up with Abbott Molecular to develop cancer tests using Rubicon's MethylPlex methylation detection technology. Under the multi-year research and option agreement, the two companies will focus primarily on noninvasive detection of prostate and bladder cancer. According to Ann Arbor, Michigan-based Rubicon, its MethylPlex technology offers a highly sensitive method for detecting the patterns of abnormal DNA methylation arising in serum and urine during tumour formation and progression.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.